Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma

被引：37

作者：

Dasanu, Constantin A. ^{[1
,2
]}

机构：

[1] Eisenhower Med Ctr, Lucy Curci Canc Ctr, Rancho Mirage, CA USA

[2] Univ Calif San Diego, San Diego, CA USA

来源：

JOURNAL OF ONCOLOGY PHARMACY PRACTICE | 2019年 / 25卷 / 08期

关键词：

MANAGEMENT; MELANOMA;

D O I：

10.1177/1078155219830166

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Nivolumab is a fully human immunoglobulin G4 immune checkpoint inhibitor antibody approved for use in the treatment of several malignancies. Severe side effects such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) have only extremely rarely been reported with this drug. We present herein a patient who developed SJS after 16 weeks of therapy with nivolumab. A week prior to this event, he developed a pruriginous papulo-erythematous rash. Prompt recognition of this phenomenon, immune checkpoint inhibitor discontinuation and steroid therapy are necessary steps in order to avoid dismal outcomes.

引用

页码：2052 / 2055

页数：4

共 11 条

[1] CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition [J].

Buchbinder, Elizabeth I. ;

Desai, Anupam .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (01) :98-106

[2]

Fakoya Adegbenro Omotuyi John, 2018, Open Access Maced J Med Sci, V6, P730, DOI 10.3889/oamjms.2018.148

[3] Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer [J].

Gettinger, Scott N. ;

Horn, Leora ;

Gandhi, Leena ;

Spigel, David R. ;

Antonia, Scott J. ;

Rizvi, Naiyer A. ;

Powderly, John D. ;

Heist, Rebecca S. ;

Carvajal, Richard D. ;

Jackman, David M. ;

Sequist, Lecia V. ;

Smith, David C. ;

Leming, Philip ;

Carbone, David P. ;

Pinder-Schenck, Mary C. ;

Topalian, Suzanne L. ;

Hodi, F. Stephen ;

Sosman, Jeffrey A. ;

Sznol, Mario ;

McDermott, David F. ;

Pardoll, Drew M. ;

Sankar, Vindira ;

Ahlers, Christoph M. ;

Salvati, Mark ;

Wigginton, Jon M. ;

Hellmann, Matthew D. ;

Kollia, Georgia D. ;

Gupta, Ashok K. ;

Brahmer, Julie R. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18) :2004-U32

[4] Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy [J].

Goldinger, Simone M. ;

Stieger, Pascale ;

Meier, Barbara ;

Micaletto, Sara ;

Contassot, Emmanuel ;

French, Lars E. ;

Dummer, Reinhard .

CLINICAL CANCER RESEARCH, 2016, 22 (16) :4023-4029

[5] Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor [J].

Guo, Liting ;

Zhang, Haijun ;

Chen, Baoan .

JOURNAL OF CANCER, 2017, 8 (03) :410-416

[6] Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy [J].

Hwang, Andrew ;

Iskandar, Andrew ;

Dasanu, Constantin A. .

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (06) :1520-1522

[7] Management of Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis: Looking Beyond Guidelines! [J].

Kumar, Rajesh ;

Das, Anupam ;

Das, Sudip .

INDIAN JOURNAL OF DERMATOLOGY, 2018, 63 (02) :117-124

[8] Stevens-Johnson syndrome during nivolumab treatment of NSCLC [J].

Salati, M. ;

Pifferi, M. ;

Baldessari, C. ;

Bertolini, F. ;

Tomasello, C. ;

Cascinu, S. ;

Barbieri, F. .

ANNALS OF ONCOLOGY, 2018, 29 (01) :283-284

[9] Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients [J].

Saw, Stephanie ;

Lee, Haur Yueh ;

Ng, Quan Sing .

EUROPEAN JOURNAL OF CANCER, 2017, 81 :237-239

[10] Management of skin adverse events associated with immune checkpoint inhibitors in patients with melanoma: A nursing perspective [J].

Thebeau, Melissa ;

Rubin, Krista ;

Hofmann, Matthias ;

Grimm, Julia ;

Weinstein, Alyona ;

Choi, Jennifer N. .

JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2017, 29 (05) :294-303

← 1 2 →